Twist Bioscience Corp Stock Performance
| TWST Stock | USD 35.17 0.68 1.90% |
The entity has a beta of 2.54, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Twist Bioscience will likely underperform. At this point, Twist Bioscience Corp has a negative expected return of -0.0089%. Please make sure to validate Twist Bioscience's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Twist Bioscience Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weak
Weak | Strong |
Over the last 90 days Twist Bioscience Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Twist Bioscience is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return (1.90) | Five Day Return (4.01) | Year To Date Return (22.38) | Ten Year Return 151.21 | All Time Return 151.21 |
1 | Twist Bioscience Unveils DNA Storage Spin-Off and Reports Strong Q2 Growth | 05/05/2025 |
2 | Twist Biosciences Buy Rating Reiterated at Guggenheim | 05/09/2025 |
3 | Twist Bioscience Expands Partnership with Element Biosciences TWST Stock News | 05/22/2025 |
4 | Disposition of 8 shares by Robert Werner of Twist Bioscience at 27.728 subject to Rule 16b-3 | 05/23/2025 |
5 | Disposition of 225 shares by Robert Werner of Twist Bioscience at 31.75 subject to Rule 16b-3 | 06/06/2025 |
6 | Disposition of 853 shares by Paula Green of Twist Bioscience at 31.75 subject to Rule 16b-3 | 06/10/2025 |
7 | Twist Bioscience Corp Shares Up 4.12 percent on Jun 11 | 06/11/2025 |
8 | Disposition of 185 shares by Robert Werner of Twist Bioscience at 49.352 subject to Rule 16b-3 | 06/13/2025 |
9 | Disposition of tradable shares by Dennis Cho of Twist Bioscience at 33.475 subject to Rule 16b-3 | 06/16/2025 |
10 | Disposition of 230 shares by Dennis Cho of Twist Bioscience at 35.755 subject to Rule 16b-3 | 06/20/2025 |
11 | Insider Selling Twist Bioscience Corporation SVP Sells 10,441.92 in Stock | 06/27/2025 |
12 | Twist Bioscience Corp Trading Down 6.03 percent on Jul 7 | 07/07/2025 |
13 | Disposition of 2449 shares by Adam Laponis of Twist Bioscience at 38.146 subject to Rule 16b-3 | 07/09/2025 |
14 | Twist Bioscience Corp Announces Upcoming Fiscal 2025 Q3 Financial Results Release TWST ... | 07/14/2025 |
15 | Disposition of 133 shares by Dennis Cho of Twist Bioscience at 46.807 subject to Rule 16b-3 | 07/18/2025 |
| Begin Period Cash Flow | 289.3 M | |
| Total Cashflows From Investing Activities | -3.1 M |
Twist Bioscience Relative Risk vs. Return Landscape
If you would invest 3,694 in Twist Bioscience Corp on April 22, 2025 and sell it today you would lose (177.00) from holding Twist Bioscience Corp or give up 4.79% of portfolio value over 90 days. Twist Bioscience Corp is currently does not generate positive expected returns and assumes 3.758% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Twist, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Twist Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Twist Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Twist Bioscience Corp, and traders can use it to determine the average amount a Twist Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0024
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TWST |
Estimated Market Risk
| 3.76 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Twist Bioscience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Twist Bioscience by adding Twist Bioscience to a well-diversified portfolio.
Twist Bioscience Fundamentals Growth
Twist Stock prices reflect investors' perceptions of the future prospects and financial health of Twist Bioscience, and Twist Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Twist Stock performance.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.55) % | ||||
| Operating Margin | (0.45) % | ||||
| Current Valuation | 1.93 B | ||||
| Shares Outstanding | 59.92 M | ||||
| Price To Book | 4.79 X | ||||
| Price To Sales | 6.06 X | ||||
| Revenue | 312.97 M | ||||
| Gross Profit | 162.37 M | ||||
| EBITDA | (176.71 M) | ||||
| Net Income | (208.73 M) | ||||
| Cash And Equivalents | 504.97 M | ||||
| Cash Per Share | 8.93 X | ||||
| Total Debt | 85.03 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 6.58 X | ||||
| Book Value Per Share | 7.35 X | ||||
| Cash Flow From Operations | (64.09 M) | ||||
| Earnings Per Share | (3.25) X | ||||
| Market Capitalization | 2.11 B | ||||
| Total Asset | 614.32 M | ||||
| Retained Earnings | (1.24 B) | ||||
| Working Capital | 275.77 M | ||||
About Twist Bioscience Performance
Assessing Twist Bioscience's fundamental ratios provides investors with valuable insights into Twist Bioscience's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Twist Bioscience is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 44.03 | 58.81 | |
| Return On Tangible Assets | (0.37) | (0.38) | |
| Return On Capital Employed | (0.37) | (0.38) | |
| Return On Assets | (0.31) | (0.32) | |
| Return On Equity | (0.51) | (0.48) |
Things to note about Twist Bioscience Corp performance evaluation
Checking the ongoing alerts about Twist Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Twist Bioscience Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Twist Bioscience generated a negative expected return over the last 90 days | |
| Twist Bioscience has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 312.97 M. Net Loss for the year was (208.73 M) with profit before overhead, payroll, taxes, and interest of 162.37 M. | |
| Twist Bioscience Corp currently holds about 504.97 M in cash with (64.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.93. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Breakeven On The Horizon For Glaukos Corporation |
- Analyzing Twist Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Twist Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Twist Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Twist Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Twist Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Twist Bioscience's stock. These opinions can provide insight into Twist Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Twist Stock Analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.